Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

NMR Spectroscopy Nature Bank Creates Limitless Opportunities for Drug Discovery

By BiotechDaily International staff writers
Posted on 28 Apr 2014
Australian researchers have developed a new tool for finding natural compounds that could form the foundation of innovative therapeutic agents. 

The corresponding author, Prof. Ronald Quinn AM from Griffith University’s Eskitis Institute for Drug Discovery (Brisbane, Australia), reported that testing the new process on a marine sponge had delivered not only validation that the system is successful, but also a potential lead in the fight against Parkinson’s disease. “We have found a new screening method which allows us to identify novel molecules drawn from nature to test for biological activity,” Prof. Quinn said. “As it happens, the first new compound we discovered through this process has demonstrated a response in Parkinson’s disease cells.” 

The findings were published online April 15, 2014, in the chemistry journal Angewandte Chemie. The first author Dr. Tanja Grkovic said the screening process involves nuclear magnetic resonance (NMR) spectroscopy; a highly sensitive instrument through which it is possible to see natural products weighing as little as 20 micrograms. “When you are searching for nature-derived molecules, the jackpot is finding something that nobody has ever seen before and rather than just a variation on a known theme,” Dr. Grkovic said. “We began the project by selecting 20 marine sponge samples randomly from Griffith’s Nature Bank facility and using the NMR technique trying to visualize all the small molecules which could meet the requirements for a potential new drug. “The idea was to look at patterns of data and identify unusual or unique sets. We followed one such pattern and isolated a natural product with a novel skeleton which has turned out to be a molecule which was completely unknown previously.” 

Griffith’s Nature Bank is a novel drug discovery resource based on natural products found in China, Australia, and Papua New Guinea. It comprises more than 45,000 samples of plants and marine invertebrates, 200,000 semipurified fractions, 3,250 pure compounds and over 600 naturally occurring fragments. 

This NMR screening process provides a new way of searching all those natural samples stored in Nature Bank and uncovering the potential biological activity of the compounds within them. 

Deputy director of the Eskitis Institute and coauthor of the paper, Assoc. Prof. George Mellick, is a specialist researcher in neurodegenerative diseases such as Parkinson’s disease. He is excitied by the research prospects this new molecule may provide. “What is very intriguing about this novel natural product is that, while we have found it has an effect on cells sourced from a Parkinson’s patient, it showed a different biological activity on cells from healthy individuals,” Assoc. Prof. Mellick said. “This provides us with a new tool to study the fundamental biology of Parkinson's and to get a better understanding of the cellular processes involved in the development of this disease.” 

The Parkinson’s response is only the beginning, according to the scientists. “This new research technique opens the door to unlimited opportunities, both in terms of chemistry and biology research at Eskitis, as we continue the search for new therapies against disease,” Prof. Quinn said.

Related Links:

Griffith University’s Eskitis Institute for Drug Discovery
 


Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.